A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors.
Izzo A, Massimino E, Riccardi G, Della Pepa G. · 2021
Read A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. by Izzo A, Massimino E, Riccardi G, Della Pepa G. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7826709.txt.
Introduction
Izzo and co-authors review sarcopenia in people with type 2 diabetes. Diabetes weighs heavily on older adults. About 25% of people over the age of 65 years have it. Sarcopenia means loss of muscle mass, strength, and function. It now counts as a diabetes complication in old age.
The authors update what is known about its frequency. They list the traits that travel with it. Age, sex, body weight, and disease length all matter. Blood sugar control and vessel complications are covered too. Diet and glucose-lowering drugs enter the picture as well. Spotting sarcopenia early could protect quality of life. The authors urge doctors and dietitians to screen for it.
Catalog record
| CREATOR | Izzo A, Massimino E, Riccardi G, Della Pepa G. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors By Anna Izzo, Elena Massimino, Gabriele Riccardi, Giuseppe Della Pepa Published in: Nutrients DOI: 10.3390/nu13010183 ABSTRACT Abstract Type 2 diabetes mellitus (T2DM) represents a major health burden for the elderly population, affecting approximately 25% of people over the age of 65 years. This percentage is expected to increase dramatically in the next decades in relation to the increased longevity of the population observed in recent years. Beyond microvascular and macrovascular complications, sarcopenia has been described as a new diabetes complication in the elderly population. Increasing attention has been paid by researchers and clinicians to this age-related condition—characterized by loss of skeletal muscle mass together with the loss of muscle power and function—in individuals with T2DM; this is due to the heavy impact that sarcopenia may have on physical and psychosocial health of diabetic patients, thus affecting their quality of life. The aim of this narrative review is to provide an update on: (1) the risk of sarcopenia in individuals with T2DM, and (2) its association with relevant features of patients with T2DM such as age, gender, body mass index, disease duration, glycemic control, presence of microvascular or macrovascular complications, nutritional status, and glucose-lowering drugs. From a clinical point of view, it is necessary to improve the ability of physicians and dietitians to recognize early sarcopenia and its risk factors in patients with T2DM in order to make appropriate therapeutic approaches able to prevent and treat this condition. Keywords: sarcopenia, type 2 diabetes mellitus, skeletal muscle mass 1. INTRODUCTION Type 2 diabetes mellitus (T2DM) is one of the most widespread metabolic diseases. The alarming rise in T2DM prevalence worldwide, exploding in both low-income countries and adolescents/young adults, as well as its heavy impact on longevity and quality of life, poses enormous challenges in the diagnosis, prevention, and treatment of this disease [1]. The improvement of the healthcare system and the advancements in prevention and treatment of major non-communicable illnesses have substantially increased the longevity of the population. Since advancing age represents a risk factor for T2DM and the improvement of health care has contributed to reduced mortality also in the diabetic population, the number of elderly people with T2DM has increased dramatically in recent years [2,3]. T2DM represents an important health burden in the elderly population, affecting approximately 25% of people over the age of 65 years; this proportion is expected to further increase in the next decades [4]. Beyond microvascular and macrovascular complications, elderly people with T2DM have higher rates of functional disability, coexisting illnesses, and several common geriatric disorders [5]. Among these, sarcopenia—a degenerative skeletal muscle condition related to the aging process—has been described as a new complication observed in the elderly population with T2DM [6]. Sarcopenia was defined for the first time in 1988 by Irwin Rosenberg as an age-related decrease in skeletal muscle mass and function [7], and ten years later Baumgartner provided a method for the evaluation of sarcopenia by using appendicular lean mass adjusted for height (kg/m2) [8]. From a physiological point of view, a progressive and generalized loss of muscle mass can be observed after the age of 40 years; the rate of deterioration has been estimated to be 8% every ten years up to 70 years, and 15–25% every ten years after this age [9]. Similarly, a 10–15% loss of leg strength every ten years has been reported to occur up to 70 years, increasing to 25–40% every ten years after this age [10]. Despite the clear notion of sarcopenia, its current evaluation in clinical practice is still not univocal. This gap is strictly related to the fact that evaluation of muscle strength, mass, quality, and performance should comprehensively be taken into account for the definition of sarcopenia. In recent years, different definitions by international consensus have been proposed. In 2010, the European Working Group on Sarcopenia in Older People developed a practical clinical definition and consensus diagnostic criteria for sarcopenia recommending to utilize the presence of both low muscle mass and low muscle function (strength or performance) [11]. In 2018, an update by the same working group was provided defining sarcopenia by low measurement levels of three parameters: muscle strength (evaluated by hand grip strength), muscle quantity/quality (evaluated by appendicular lean mass or skeletal muscle mass), and physical performance (evaluated by gait speed or short physical performance battery) as an indicator of severity [12]. Similarly, the Asian Working Group for Sarcopenia developed its own consensus—the only difference being in cut-off values, in consideration of the anthropometric characteristics of the Asian population [13]. Reduction in muscle mass and physical performance were included in the definition of sarcopenia by the International Working Group on Sarcopenia [14], while reduction in muscle mass and strength were included in the diagnostic criteria proposed by the American Foundation for the National Institutes of Health [15]. The prevalence of sarcopenia worldwide ranges from 10% to 40%, based on the different characteristics of the population and the different criteria to asses it [16]. In non-Asian countries, the prevalence is higher than in Asian ones, without differences between genders [17]. Furthermore, the prevalence of sarcopenia is higher in acutely hospitalized older patients [18] or in patients admitted to post-acute geriatric rehabilitation [19]. In fact, sarcopenia is associated with poor health outcomes—such as cognitive impairment and functional decline [20,21], depression [22], falls and fractures [23], and mortality [21]—and can be considered the main physical drivers of frailty or perhaps even a precursor state. Sarcopenia and frailty are strictly related and lead to difficulties performing daily living activities and increased disability [24]. Frailty is a condition in which the individual is highly vulnerable to stressors that lead to disability, dependency, and mortality with decreased physical reserves [25,26]. The most common definition used for frailty is the frailty phenotype, consisting of five physical components to define frailty: unintentional weight loss, self-reported exhaustion, weakness, slow walking speed, and low physical activity [27]. Individuals are considered to be frail when they meet three or more criteria, and they are considered to be robust when they have none. The Frailty Index is another popular approach describing frailty as a state caused by the accumulation of health deficits during the life course. It is calculated as the ratio of the number of deficits present in the individual to the number of total deficits considered [28]. The Edmonton Frail Scale (EFS) [29], its recent validated short version (EFS-SF) [30,31], the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) Score [32], the Geriatricians’ Clinical Impression of Frailty (GCIF) scale [33], and the Clinical-Functional Vulnerability Index-20 (IVCF-20) [34] are other approaches able to identify frailty. It is important to underline that the progressive increase in obesity worldwide configures a new public health problem: sarcopenic obesity, a condition in which sarcopenia and obesity are coexisting [35]. Sarcopenic obesity might be related to different factors such as aging, reduction in physical activity, malnutrition, sub-clinical inflammation, and hormonal changes [36]. Dramatically, the clinical consequences of sarcopenic obesity are much greater than sarcopenia alone; in fact, several studies reported that sarcopenic obesity is associated with higher fasting blood glucose, insulin resistance, blood pressure, plasma lipid abnormalities, T2DM, cardiovascular diseases, and